Amneal Pharmaceuticals, Inc.
AMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001723128
No open-market purchases or sales by Amneal Pharmaceuticals, Inc. insiders were filed in the last 90 days; 312 institutions reported holding it in 13F filings for Q2 2026, worth $2.82B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022! | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 15, 2025 | Jan 10, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Cost of revenue | $1.91B | $1.77B | $1.57B | $1.42B | $1.30B |
| Gross profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M |
| Research and development | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M |
| Selling, general and administrative | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M | $152.7M |
| Income tax | $11.3M | $18.9M | $8.45M | $6.66M | $11.2M |
| Net income | $72.1M | -$73.9M | -$79.3M | -$270.6M | $13.2M |
| EPS, basic | $0.23 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| EPS, diluted | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Weighted shares, basic | 313.4M | 309.0M | 176.1M | 150.9M | 148.9M |
| Weighted shares, diluted | 324.8M | 309.0M | 176.1M | 150.9M | 151.8M |
| Margins and growth | |||||
| Gross margin | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% |
| Operating margin | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% |
| Net margin | 2.4% | -2.6% | -3.3% | -12.2% | 0.6% |
| Revenue growth, year over year | +8.0% | +16.7% | +8.2% | +5.7% | +5.1% |
| Net income growth, year over year | – | – | – | −2,155.6% | −85.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 15, 2025 | Jan 10, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Cash and equivalents | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M |
| Accounts receivable | – | – | – | $741.8M | $662.6M |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M |
| Total current assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B |
| Property, plant and equipment | $442.9M | $424.9M | $447.6M | $469.8M | $514.2M |
| Goodwill | $595.5M | $597.4M | $598.6M | $598.9M | $593.0M |
| Intangible assets | $563.5M | $732.4M | $890.4M | $1.10B | $1.17B |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B |
| Accounts payable | – | – | – | $166.0M | $131.1M |
| Short-term debt | $6.76M | $224.2M | $34.1M | $30.0M | $30.6M |
| Total current liabilities | $881.6M | $1.13B | $846.6M | $752.8M | $677.2M |
| Long-term debt | $2.57B | $2.16B | $2.39B | $2.59B | $2.68B |
| Shareholders' equity | -$71.3M | -$109.5M | $20.0M | $184.0M | $367.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 15, 2025 | Jan 10, 2024 | Jan 10, 2023 | Jan 11, 2022 |
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M |
| Capital expenditures | $70.1M | $51.9M | $43.2M | $46.4M | $47.7M |
| Free cash flow | $269.9M | $243.2M | $302.4M | $18.7M | $194.1M |
| Stock-based compensation | $32.0M | $27.8M | $26.8M | $31.8M | $28.4M |
| Investing cash flow | -$112.3M | -$63.0M | -$69.2M | -$174.3M | -$194.2M |
| Financing cash flow | -$31.5M | -$211.8M | -$212.6M | -$106.6M | -$138.1M |
| Net change in cash | $194.5M | $19.3M | $63.9M | -$221.5M | -$90.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.1% | 1.0% | 1.1% | 1.4% | 1.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 348.4M | +10.8% | SEC |
| Jul 31, 2026 | 319.4M | +1.7% | SEC |
| Apr 30, 2026 | 319.0M | +1.8% | SEC |
| Feb 13, 2026 | 314.6M | +1.5% | SEC |
| Oct 31, 2025 | 314.4M | +1.5% | SEC |
| Jul 31, 2025 | 314.1M | +1.5% | SEC |
| Apr 30, 2025 | 313.4M | +1.5% | SEC |
| Feb 14, 2025 | 310.0M | +1.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.